Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, talk about the practical use of biomarkers in treatment decision making.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
Experts discuss the use of serum NFL levels in clinical practice, focusing on diagnosis, prognosis, and treatment monitoring.
They raise questions about establishing a baseline NFL level at diagnosis and its implications. Tanuja Chitnis, MD, suggests waiting 2 to 3 months after a stable period, considering the impact of steroids used to treat attacks.
They discuss the importance of understanding baseline levels and the potential correlation with future disease progression. Ahmed Obeidat, MD, PhD, emphasizes the significance of monitoring NFL levels over time, especially post-treatment initiation. He suggests re-baselining every 3 to 6 months, helping assess treatment efficacy and potentially reconsidering the diagnosis if NFL remains persistently elevated.
Mark Freedman, MD, MSc, probes into the prognostic value of peak NFL levels, referencing data indicating a correlation with brain atrophy over 10 years. Experts note that early NFL measures provide some predictive value, but continuous monitoring may not significantly enhance prognostic models.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
